Risk factors of nonalcoholic fatty liver disease with a normal visceral adipose tissue area

Huang ZhiPeng; Jiang JianJia; Huang ZiCheng; Guo GuiYuan; Zhou APei; Liu XiaoQiang

doi:10.3969/j.issn.1001-5256.2019.05.025

Volume 35 Issue 5

May 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(5): 1061-1064

PDF( 1910 KB)

Risk factors of nonalcoholic fatty liver disease with a normal visceral adipose tissue area

DOI: 10.3969/j.issn.1001-5256.2019.05.025

Department of Gastroenterology, Quanzhou First Hospital Affiliated to Fujian Medical University

Research funding:

Received Date: 2018-10-15
Published Date: 2019-05-20

Abstract

Abstract

Objective To investigate the risk factors and insulin resistance ( IR) of nonalcoholic fatty liver disease ( NAFLD) with a normal visceral adipose tissue ( VAT) area. Methods A total of 45 NAFLD persons with a normal VAT area who were admitted to Quanzhou First Hospital Affiliated to Fujian Medical University from June 2017 to May 2018 were enrolled as observation group, and 27 non-NAFLD patients with a normal VAT area were enrolled as control group. VAT area, waist circumference, fasting blood glucose ( FBG) , and fasting insulin ( FINS) were measured for both groups, homeostasis model assessment of insulin resistance ( HOMA-IR) was calculated, and the correlation of IR with the indices including waist circumference was analyzed. The independent samples t-test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between groups. Pearson correlation analysis and Spearman correlation analysis were used to investigate the correlation of normally and non-normally distributed continuous data. A forward logistic regression analysis was used to identify related risk factors. Results The NAFLD group had a significantly higher level of IR than the control group, and there was a significant difference in HOMA-IR between the two groups ( 2. 66 ( 1. 59-4. 06) vs 1. 84 ( 1. 25-2. 47) , Z = 364. 000, P = 0. 005) . IR was positively correlated with FBG ( r = 0. 412, P = 0. 005) , FINS ( r = 0. 789, P <0. 001) , and TG ( r = 0. 306, P = 0. 041) . IR was negatively correlated with HDL ( r =-9. 398, P = 0. 007) . The multivariate regression analysis showed that waist circumference was an independent risk factor for NAFLD with a normal VAT area ( regression coefficient = 0. 181, odds ratio = 1. 198, 95% confidence interval: 1. 099-1. 306, P < 0. 001) . Conclusion There is a certain degree of IR in NAFLD patients with a normal VAT, and waist circumference is an independent risk for NAFLD with a normal VAT.
- non-alcoholic fatty liver disease,
- intra-abdominal fat,
- risk factors

FullText(HTML)

References(20)

References

[1] ZELBER-SAGI S, RATZIU V, OREN R. Nutrition and physical activity in NAFLD:An overview of the epidemiological evidence[J]. World Gastroenterol, 2011, 17 (29) :3377-3389.

[2] FABBRINI E, SULLIVAN S, KLEIN S. Obesity and nonalcoholic fatty liver disease:Biochemical, metabolic, and clinical implications[J]. Hepatology, 2010, 51:679-689.

[3] MARGARITI E, DEUTSCH M, MANOLAKOPOULOS S, et al.Nonalcoholic fatty liver disease may develop in individuals with normal body mass index[J]. Ann Gastroenterol, 2012, 25 (1) :45-51.

[4] HUANG ZP, SU ZJ, JIANG JJ, et al. The analysis of the relationship between the extence of non-alcoholic fatty liver disease and metabolic syndrome’s components[J]. Clin Med China, 2013, 29 (11) :1158-1161. (in Chinese) 黄志鹏, 苏智军, 蒋建家, 等.非酒精性脂肪肝严重程度与代谢综合征组分的相关性分析[J].中国综合临床, 2013, 29 (11) :1158-1161.

[5] ZHAO ZG. Relationship between C-reactive protein and visceral fat obesity and their impacts on target organ damage[D]. Chongqing:The Third Military Medical University, 2009. (in Chinese) 赵志钢. C反应蛋白与内脏脂肪型肥胖及其相关靶器官损害的关系[D].重庆:第三军医大学, 2009.

[6] The Chinese National Workshop on Fatty Liver and Alcoholic Liver Disease for the Chinese Liver Disease Association.Guidelines for management of nonalcoholic fatty liver diseas[J]. J Clin Hepatol, 2010, 26 (2) :120-124. (in Chinese) 中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].临床肝胆病杂志, 2010, 26 (2) :120-124.

[7] Department of Disease Control, Ministry of Health of the People’s Republic of China. Guide-lines for prevention and control of overweight and obesity in Chinese adults (Excerpt) [J]. Acta Nutrimenta Sinica, 2004, 26 (1) :1-4. (in Chinese) 中华人民共和国卫生部疾病控制司.中国成人超重和肥胖症预防与控制指南 (节录) [J].营养学报, 2004, 26 (1) :1-4.

[8] CHUNG GE, KIM D, KWARK MS, et al. Visceral adipose tissue area as an independent risk factor for elevated liver enzyme in nonalcoholic fatty liver disease[J]. Medicine, 2015, 94 (9) :1-8.

[9] KIM D, KIM WR. Nonobese fatty liver disease[J]. Clin Gastroenterol Hepatol, 2017, 15 (4) :474-485.

[10] GONZALEZ-CANTERO J, MARTIN-RODRIGUEZ JL, GONZALEZ-CANTERO A, et al. Effect of cholecystectomy on hepatic fat accumulation and insulin resistance in non-obese his-panic patients:A pilot study[J]. Lipids Health Dis, 2017, 16 (1) :129.

[11] BUGIANESI E, ZANNONI C, VANNI E, et al. Non-alcoholic fatty liver and insulin resistance:A cause-effect relationship?[J]. Dig Liver Dis, 2004, 36 (3) :165-173.

[12] BHAT G, BABA CS, PANDEY A, et al. Life style modification improves insulin resistance and liver histology in patients with non-alcoholic fatty liver disease[J]. World J Hepatol, 2012, 4 (7) :209-217.

[13] LI C, GUO P, OKEKUNLE AP, et al. Lean non-alcoholic fatty liver disease patients had compareable total caloric, carbohydrate, protein, fat, iron, sleep duration and overtime work as obese non-alcoholic fatty liver diseasepatients[J]. J Gastroenterol Hepatol, 2018.[Epub ahead of print]

[14] DAS K, DAS K, MUKHERJEE PS, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease[J]. Hepatology, 2010, 51:1593-1602.

[15] KUMAR R, MOHAN S. Non-alcoholic fatty liver disease in lean subjects:Characteristics and Implications[J]. J Clin Transl Hepatol, 2017, 5 (3) :216-223.

[16] BHAT G, BABA CS, PANDEY A, et al. Insulin resistance and metabolic syndrome in non-obese Indian patients with nonalcoholic fatty liver disease[J]. Trop Gastroenterol, 2013, 34 (1) :18-24.

[17] GONZALEZ-CANTERO J, MARTIN-RODRIGUEZ JL, GONZALEZ-CANTERO A, et al. Insulin resistance in lean and overweight non-diabetic Caucasian adults:Study of its relationship with liver triglyceride content, waist circumference and BMI[J]. PLo S One, 2018, 13 (2) :1-13.

[18] FRACANZANI AL, VALENTI L, BUGIANESI E, et al. Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity[J]. J Hepatol, 2011, 54:1244-1249.

[19] SOOKOIAN S, PIROLA CJ. Systematic review with meta-analysis:Risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile betweenn lean and obese patients[J]. Aliment Pharmacol Ther, 2017, 46 (2) :85-95.

[20] LENG XJ, YAN XB. Efficiency of FibroTouch in evaluating liver fibrosis degree in nonalcoholic fatty liver disease patients with different levels of body mass index[J]. J Clin Hepatol, 2018, 34 (9) :1891-1895. (in Chinese) 冷雪君, 颜学兵. FibroTouch对不同BMI水平非酒精性脂肪性肝病患者肝纤维化程度的评估比较[J].临床肝胆病杂志, 2018, 34 (9) :1891-1895.

Relative Articles

[1]	Wang ZhiXin, Li Yao, Zhou LiuXin, Ren Li, Qu Kai, Miao Run, Hou LiChao, Wang HaiJiu, Liu Chang, Fan HaiNing. Influence of 5-hydroxytryptamine and platelet count in peripheral blood on the prognosis of patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(7): 1534-1539. doi: 10.3969/j.issn.1001-5256.2020.07.017
[2]	Lu Qian, Zhu Li, Cheng Xin, Huang Hua, Chen Zhong. Expression of proteasome subunit beta type 4 in hepatocellular carcinoma and its association with prognosis[J]. Journal of Clinical Hepatology, 2020, 36(2): 372-376. doi: 10.3969/j.issn.1001-5256.2020.02.028
[3]	Zhang DaLi, Feng DanNi, Zhang LiJuan, Tang RuJia, He Xi, Zhou Xia, Gao YinJie, Liu ZhenWen, Liu HongLing. Risk factors for recurrence after liver transplantation in patients with hepatocellular carcinoma and their prognosis[J]. Journal of Clinical Hepatology, 2020, 36(9): 1985-1989. doi: 10.3969/j.issn.1001-5256.2020.09.015
[4]	Ye YingJian, Liu Bo, Chen Wei, Li QiongXia. Prognosis and staging system analysis of hepatocellular carcinoma patients with negative serum alpha-fetoprotein[J]. Journal of Clinical Hepatology, 2019, 35(3): 535-541. doi: 10.3969/j.issn.1001-5256.2019.03.017
[5]	Zang YouYa, Long PeiYun, Han ZhiWei, Wang Huan, Ruan JingSheng, Huang Shan, Wu GuoBin, Chen Chuang. Establishment and verification of a nomogram for predicting patient prognosis after hepatectomy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(10): 2225-2230. doi: 10.3969/j.issn.1001-5256.2019.10.019
[6]	Chen Chuang, Long PeiYun, Chen Jie, Wang Pan, Huang QingYun, Zang YouYa, Deng GuoYu, Lin DongYi, Wang ZongYu. Value of Barcelona Clinic Liver Cancer staging system versus Hong Kong Liver Cancer staging system in predicting the prognosis of patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(3): 530-534. doi: 10.3969/j.issn.1001-5256.2019.03.016
[7]	Tang Ling, Qiu LuDie, Qin Wen, Wu Gang. Expression of circular RNA FLI1 in patients with hepatocellular carcinoma and its association with prognosis[J]. Journal of Clinical Hepatology, 2019, 35(9): 1980-1984. doi: 10.3969/j.issn.1001-5256.2019.09.019
[8]	Luo Hao, Huang Jun. Clinical value of albumin-bilirubin grade in evaluating the prognosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(7): 1608-1612. doi: 10.3969/j.issn.1001-5256.2019.07.040
[9]	He YaJing, Zhang ZhiMing, He WeiMeng, Hou JinLin. Epidemiological characteristics and prognosis of hepatocellular carcinoma: A single-center observational real-world cohort study of 1302 cases[J]. Journal of Clinical Hepatology, 2019, 35(5): 1002-1007. doi: 10.3969/j.issn.1001-5256.2019.05.014
[10]	Zhu Feng, Feng XiaoHai, An Yue. Association between the expression of somatostatin receptors and pathological features, prognosis in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(2): 314-320. doi: 10.3969/j.issn.1001-5256.2018.02.019
[11]	Yang GuiMin, Zhao YunSheng, Wang ChunHua, Jin Liang. Research advances in tumor markers for the diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(1): 199-203. doi: 10.3969/j.issn.1001-5256.2018.01.044
[12]	Xia DongDong, Wang EnXin, Wang WenJun, Bai Wei, Yuan Jie, Han GuoHong. Early alpha-fetoprotein response can predict the prognosis of patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization[J]. Journal of Clinical Hepatology, 2017, 33(6): 1120-1125. doi: 10.3969/j.issn.1001-5256.2017.06.021
[13]	Ma ShiJie, Zou ShaoJing, Luo XiaoLing, Li QianJun, Huang JiaSheng. Prognostic factors for transcatheter arterial chemoembolization in patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(1): 80-83. doi: 10.3969/j.issn.1001-5256.2016.01.013
[14]	Wang XianBo, Gao FangYuan, Liu Yao. Neutrophil- lymphocyte ratio: a novel predictor of clinical outcome of patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(4): 649-652. doi: 10.3969/j.issn.1001-5256.2016.04.007
[15]	Yang XiaoXiao, Ma Hong. Research advances in tumor markers of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(4): 811-815. doi: 10.3969/j.issn.1001-5256.2016.04.047
[16]	Li Peng, Zhai Yun, Zhang ShiBin, Li Lei, Ding HuiGuo. Analysis of quality of life and prognosis in patients with HBV-related end-stage hepatocellular carcinoma after antiviral therapy[J]. Journal of Clinical Hepatology, 2015, 31(5): 721-724. doi: 10.3969/j.issn.1001-5256.2015.05.021
[17]	Wang JianGang, Li HuaCheng, Fei XinYing. Application of metabolomics in research on biomarkers for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(8): 836-838. doi: 10.3969/j.issn.1001-5256.2014.08.039
[18]	Jia Jia, Qi XingShun, Han GuoHong. Prognostic value of α-fetoprotein response in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2013, 29(8): 576-580. doi: 10.3969/j.issn.1001-5256.2013.08.006
[19]	Zhang LiJun, Jia XiaoFang, Teng ZhenLin, Cheng NengNeng. Biomarkers of liver cancer related to hepatitis B virus selected by proteomics[J]. Journal of Clinical Hepatology, 2011, 27(5): 553-557.
[20]	Ren YiBin, Wang HongYang. The progress of diagnostic marker in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2010, 26(4): 358-360+364.

Supplements(0)

Cited By

Cited by

Periodical cited type(11)

1.	顾智文. 射频消融术联合奥沙利铂加卡培他滨方案用于结直肠癌术后肝转移患者的临床价值. 大医生. 2024(01): 25-28 .
2.	刘炫鳞，买佳琪，马文兵. 脾多肽注射液联合西妥昔、mFOLFOX6方案对直肠癌肝转移患者生存质量及TRF1、TRF2表达的影响. 临床医学研究与实践. 2023(25): 29-32 .
3.	林守英，周庄，刘丽雅. 薏苡附子败酱散联合XELOX方案对结直肠癌患者免疫功能、肠道菌群的影响. 实用中西医结合临床. 2023(21): 37-40 .
4.	张洋，杨帆，王景景. 沙利度胺联合XELOX方案化疗治疗转移性结直肠癌的疗效及对生存率的影响. 癌症进展. 2022(07): 727-730 .
5.	苏华冠，谢礼福，刘奕武，赖光芒. 腹腔镜下结直肠癌切除术联合肝转移瘤射频消融术治疗结直肠癌肝转移. 中国肝脏病杂志(电子版). 2021(02): 13-18 .
6.	王强. 经皮肝射频消融术联合经导管肝动脉灌注化疗治疗晚期结直肠癌多发肝转移瘤患者的效果. 中国民康医学. 2021(23): 19-22 .
7.	刘信，刘放，刘也夫，谢峰，张睿. 术中开腹彩超引导下射频与经皮CT引导射频治疗结直肠癌肝转移疗效比较研究. 临床军医杂志. 2020(02): 167-169 .
8.	高岩，蓝宇，贾纯增. 内镜黏膜下剥离术治疗早期结直肠癌及癌前病变临床效果观察. 临床军医杂志. 2020(06): 668-671+675 .
9.	吕厚宽，庄文辉，刘晓晖，郭泽才，刘琪. 卡培他滨联合奥沙利铂治疗直肠癌的临床疗效研究. 长春中医药大学学报. 2020(04): 741-744 .
10.	李江，候宇，蔡晓蓓，徐承雷，易根发. 基于限制性肝段切除手术的局部治疗模式改善结直肠癌术后肝脏寡转移的预后分析. 临床肝胆病杂志. 2020(08): 1763-1767 . 本站查看
11.	彭文杰. AFP、CCL2和HP在结直肠癌肝转移诊断中的临床应用研究. 国际生物医学工程杂志. 2019(05): 414-418 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1547) PDF downloads(309)

Risk factors of nonalcoholic fatty liver disease with a normal visceral adipose tissue area

DOI: 10.3969/j.issn.1001-5256.2019.05.025